Methods for the diagnosis of genitourinary cancer
Patent Number: US8101371
Executive Summary:
General Description:
A method of diagnosing genitourinary (GU) cancer in a subject comprising detecting elevated thromboxane receptor (TP) β, as compared to normal controls, in the urine, semen or prostatic fluid of the subject. Detecting may comprise immunologic detection, such as an ELISA or lateral flow assay. Detection may more specifically comprise exposing urine to a support comprising a first anti-TPβ antibody, and may further comprise exposing TPβ bound to the first anti-TPβ antibody to a second anti-TPβ antibody, the first and second anti-TPβ antibodies binding to different epitopes, such as where the second anti-TPβ antibody comprises a detectable label or where the second anti-TPβ is detected using an anti-Fc antibody that is labeled with a detectable marker. The support may be a membrane, a dipstick, a multi-well dish, a filter, a bead, or a biochip. The GU cancer may be bladder cancer, prostate cancer, urethral cancer or renal cancer, and the bladder cancer may be invasive, superficial or metastatic bladder cancer. The subject may previously have been diagnosed with, and successfully treated for, GU cancer.
Strengths:
Patent Status:
Inventor Bio: Perry V. Halushka
http://academicdepartments.musc.edu/pharmacology/faculty/halushka.htm
Executive Summary:
- Invention Type: Diagnostic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US8101371/
- Research Institute: Medical University of South Carolina
- Disease Focus: Genitourinary cancer
- Basis of Invention: A method of detecting bladder cancer in a subject comprising detecting elevated thromboxane receptor β protein expression, as compared to normal controls, in the urine of said subject
- Lead Challenge Inventor: Perry V. Halushka
- Inventors: Omar Moussa, Dennis K. Watson, Perry V. Halushka
- Development Stage: Validated in patient samples
- Novelty:
- A more sensitive and more specific early detection tool
- Clinical Applications:
- Diagnostic tool for genitourinary cancer leading to early detection
General Description:
A method of diagnosing genitourinary (GU) cancer in a subject comprising detecting elevated thromboxane receptor (TP) β, as compared to normal controls, in the urine, semen or prostatic fluid of the subject. Detecting may comprise immunologic detection, such as an ELISA or lateral flow assay. Detection may more specifically comprise exposing urine to a support comprising a first anti-TPβ antibody, and may further comprise exposing TPβ bound to the first anti-TPβ antibody to a second anti-TPβ antibody, the first and second anti-TPβ antibodies binding to different epitopes, such as where the second anti-TPβ antibody comprises a detectable label or where the second anti-TPβ is detected using an anti-Fc antibody that is labeled with a detectable marker. The support may be a membrane, a dipstick, a multi-well dish, a filter, a bead, or a biochip. The GU cancer may be bladder cancer, prostate cancer, urethral cancer or renal cancer, and the bladder cancer may be invasive, superficial or metastatic bladder cancer. The subject may previously have been diagnosed with, and successfully treated for, GU cancer.
Strengths:
- Promising biomarker for early detection in bladder, prostate, urethral, or renal cancer using less invasive sample collection.
- Early detection tool
Patent Status:
- Filing date – 2008-10-17
- Publication date – 2012-01-24
- Grant date – 2012-01-24
Inventor Bio: Perry V. Halushka
http://academicdepartments.musc.edu/pharmacology/faculty/halushka.htm
|
Visit us on Social Media
|
The FCSC
|
About Us
|
|
The Center for Advancing Innovation © 2017